Počet záznamů: 1  

Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines

  1. 1.
    0191582 - UMG-J 20033049 RIV GR eng J - Článek v odborném periodiku
    Indrová, Marie - Bubeník, Jan - Mikyšková, Romana - Mendoza, Luis - Šímová, Jana - Bieblová, Jana - Jandlová, Táňa - Jinoch, P. - Šmahel, M. - Vonka, V. - Pajtasz-Piasecka, E.
    Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    International Journal of Oncology. Roč. 22, č. 3 (2003), s. 691-695. ISSN 1019-6439
    Grant CEP: GA MZd NC7148; GA ČR GA301/00/0114; GA ČR GA301/01/0985; GA AV ČR IAA5052203; GA AV ČR IAA7052002
    Grant ostatní:KBN(PL) P04A12314; Liga proti rakovině(CZ) -
    Výzkumný záměr: CEZ:AV0Z5052915
    Klíčová slova: chemotherapy-induced residual tumour disease * immunotherapy * HPV16-associated tumours
    Kód oboru RIV: FD - Onkologie a hematologie
    Impakt faktor: 2.536, rok: 2003

    The effectiveness of chemoimmunotherapy with ifosfamide derivative CBM-4A and recombinant IL-2, IL-12, GM-CSF, or genetically modified, cytokine-producing tumour vaccines was examined in mice carrying HPV16-associated, MHC class I+ and class I- tumours. In mice carrying the MHC class I- tumour the effects of adjuvant cytokine therapy were substantially weaker than in mice carrying MHC class I+ tumour inoculum.
    Trvalý link: http://hdl.handle.net/11104/0087324
     

Počet záznamů: 1